

A controlled, double-blind, randomized study on the effect of
299V in patients with irritable bowel syndrome

European Journal of Gastroenterology and Hepatology
13, 1143-1147

DOI: 10.1097/00042737-2001110000-00004

Citation Report

#	ARTICLE	IF	CITATIONS
1	L. plantarum 299V may be beneficial in irritable bowel syndrome. Inpharma Weekly, 2001, &NA;, 10.	0.0	0
2	Probiotics for irritable bowel syndrome: a light in the darkness?. European Journal of Gastroenterology and Hepatology, 2001, 13, 1135-1136.	0.8	18
3	New and emerging treatments for irritable bowel syndrome and functional dyspepsia. Expert Opinion on Emerging Drugs, 2002, 7, 91-98.	1.0	6
5	Gut bacteria and health foods—the European perspective. International Journal of Food Microbiology, 2002, 78, 99-117.	2.1	236
6	Irritable bowel syndrome. Current Treatment Options in Gastroenterology, 2002, 5, 267-278.	0.3	7
7	Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek, 2002, 82, 279-289.	0.7	737
8	Treatment of irritable bowel syndrome. Current Treatment Options in Gastroenterology, 2003, 6, 329-337.	0.3	8
9	Using probiotics and prebiotics to improve gut health. Drug Discovery Today, 2003, 8, 692-700.	3.2	315
10	The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Alimentary Pharmacology and Therapeutics, 2003, 18, 495-505.	1.9	80
11	Irritable bowel syndrome: evaluation and treatment. Gastroenterology Clinics of North America, 2003, 32, 507-529.	1.0	14
12	Potential Uses of Probiotics in Clinical Practice. Clinical Microbiology Reviews, 2003, 16, 658-672.	5.7	703
13	Chronic fatigue syndrome: lactic acid bacteria may be of therapeutic value. Medical Hypotheses, 2003, 60, 915-923.	0.8	82
14	Probiotic use in children. Journal of Pediatric Health Care, 2003, 17, 277-283.	0.6	32
15	Pharmacologic therapy for the irritable bowel syndrome. American Journal of Gastroenterology, 2003, 98, 750-758.	0.2	81
16	Epidemiology, pathogenesis and treatment of irritable bowel syndrome. Expert Opinion on Therapeutic Patents, 2003, 13, 1213-1267.	2.4	0
17	Probiotics As Functional Foods. Nutrition in Clinical Practice, 2003, 18, 497-506.	1.1	71
18	Probiotics for Chronic Intestinal Disorders. American Journal of Gastroenterology, 2003, 98, 520-521.	0.2	13
19	Novel therapies in the treatment of irritable bowel syndrome. Expert Opinion on Investigational Drugs, 2003, 12, 635-645.	1.9	4

#	ARTICLE	IF	CITATIONS
20	Are Probiotics Useful In Irritable Bowel Syndrome?. Journal of Clinical Gastroenterology, 2003, 37, 93-94.	1.1	5
21	The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. European Journal of Gastroenterology and Hepatology, 2003, 15, 313-315.	0.8	100
22	Management of irritable bowel syndrome. European Journal of Gastroenterology and Hepatology, 2003, 15, 679-696.	0.8	13
23	Treatment of Pouchitis. Topics in Clinical Nutrition, 2003, 18, 162-169.	0.2	0
25	Beverages in Nutrition and Health. , 2004, , .		5
26	The intestinal microbiota and probiotics in irritable bowel syndrome. Scandinavian Journal of Nutrition, 2004, 48, 32-36.	0.2	3
27	Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chinese Journal of Digestive Diseases, 2004, 5, 169-174.	1.1	96
28	New pathophysiological mechanisms in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2004, 20, 1-9.	1.9	165
29	Diagnosis and therapy of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2004, 20, 10-22.	1.9	37
30	Meta-analysis: the treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2004, 20, 1253-1269.	1.9	180
31	Irritable bowel syndrome. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 315-321.	1.0	41
32	Treatment options in irritable bowel syndrome. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 773-786.	1.0	27
33	Probiotics inhibit nuclear factor- κ B and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology, 2004, 127, 1474-1487.	0.6	307
34	Comparative efficacy of dioctahedral smectite (Smecta [®]) and a probiotic preparation in chronic functional diarrhoea. Digestive and Liver Disease, 2004, 36, 824-828.	0.4	35
35	Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology, 2004, 127, 826-837.	0.6	171
36	Probiotics in The Treatment of Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2004, 38, S104-S106.	1.1	140
37	Irritable bowel syndrome: a systematic review. Clinics in Family Practice, 2004, 6, 647-669.	0.3	6
38	Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2005, 39, S230-S242.	1.1	36

#	ARTICLE	IF	CITATIONS
39	Irritable bowel syndrome and probiotics: from rationale to clinical use. <i>Current Opinion in Gastroenterology</i> , 2005, 21, 697-701.	1.0	31
40	Use of Diet and Probiotic Therapy in the Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S243-S246.	1.1	42
41	Probiotics Used in Human Studies. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 469-484.	1.1	55
42	Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome " a longitudinal study in IBS and control subjects. <i>FEMS Immunology and Medical Microbiology</i> , 2005, 43, 213-222.	2.7	262
43	Probiotic and other functional microbes: from markets to mechanisms. <i>Current Opinion in Biotechnology</i> , 2005, 16, 204-211.	3.3	344
44	Probiotics: facts and myths. <i>Clinical Microbiology and Infection</i> , 2005, 11, 958-966.	2.8	237
45	The nutrition and health benefits of yoghurt. <i>International Journal of Dairy Technology</i> , 2005, 58, 1-12.	1.3	151
46	Probiotics and gastrointestinal diseases. <i>Journal of Internal Medicine</i> , 2005, 257, 78-92.	2.7	164
47	Effect of <i>E. coli</i> Nissle 1917 on post-inflammatory visceral sensory function in a rat model. <i>Neurogastroenterology and Motility</i> , 2005, 17, 410-414.	1.6	35
48	A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 387-394.	1.9	322
49	The Probiotic Approach: An Alternative Treatment Option in Urology. <i>European Urology</i> , 2005, 47, 288-296.	0.9	63
50	The efficacy of ATCC 55730 in the treatment of patients with irritable bowel syndrome" a double blind, placebo-controlled, randomized study. <i>Clinical Nutrition</i> , 2005, 24, 925-931.	2.3	190
51	A diet based on wheat bread baked with lactic acid improves glucose tolerance in hyperinsulinaemic Zucker (fa/fa) rats. <i>Journal of Cereal Science</i> , 2005, 42, 300-308.	1.8	9
52	Functional diarrhea. <i>Current Gastroenterology Reports</i> , 2005, 7, 350-357.	1.1	8
53	Assessment of a bioactive compound for its potential antiinflammatory property by tight junction permeability. <i>Phytotherapy Research</i> , 2005, 19, 1009-1012.	2.8	8
55	Bioecological control of organ failure: The role of enteral nutrition, probiotics and synbiotics. <i>Journal of Organ Dysfunction</i> , 2005, 1, 6-17.	0.3	1
56	Probiotics under the regulatory microscope. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 1135-1143.	1.0	22
57	Potential future therapies for Irritable Bowel Syndrome: Will Disease Modifying Therapy as Opposed to Symptomatic Control Become a Reality?. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 337-354.	1.0	5

#	ARTICLE	IF	CITATIONS
58	The Use of Probiotics in Functional Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 533-545.	1.0	19
59	Bioecologic Control of the Gastrointestinal Tract: The Role of Flora and Supplemented Probiotics and Synbiotics. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 413-436.	1.0	64
60	Defining the predictors of the placebo response in irritable bowel syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 237-247.	2.4	97
61	The Role of Food Intolerance in Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 247-255.	1.0	44
62	Live bacterial cells as orally delivered therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1281-1301.	1.4	10
63	Interactions Between Commensal Bacteria and Gut Sensorimotor Function in Health and Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 2560-2568.	0.2	291
64	The Use of <i>Lactobacillus GG</i> in Irritable Bowel Syndrome in Children: A Double-blind Randomized Control Trial. <i>Journal of Pediatrics</i> , 2005, 147, 197-201.	0.9	240
65	Major depressive disorder: probiotics may be an adjuvant therapy. <i>Medical Hypotheses</i> , 2005, 64, 533-538.	0.8	225
66	Probiotic therapy for the prevention and treatment of <i>Clostridium difficile</i> -associated diarrhea: a systematic review. <i>Cmaj</i> , 2005, 173, 167-170.	0.9	174
67	Use of Probiotics in Humans: An Analysis of the Literature. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 547-570.	1.0	42
68	<i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. <i>Gastroenterology</i> , 2005, 128, 541-551.	0.6	1,276
69	Probiotics: An ideal anti-inflammatory treatment for IBS?. <i>Gastroenterology</i> , 2005, 128, 783-785.	0.6	31
70	Probiotics as a Treatment Strategy for Gastrointestinal Diseases?. <i>Digestion</i> , 2005, 72, 57-68.	1.2	71
71	Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR. <i>American Journal of Gastroenterology</i> , 2005, 100, 373-382.	0.2	608
72	Irritable Bowel Syndrome. <i>Drugs</i> , 2006, 66, 1073-1088.	4.9	64
74	Probiotics: their role in the treatment and prevention of disease. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 261-275.	2.0	138
75	Functions of the Human Intestinal Flora: The Use of Probiotics and Prebiotics. , 0, , 174-207.		1
76	Gastrointestinal Microflora: Probiotics. <i>Advances in Applied Microbiology</i> , 2006, 59, 187-219.	1.3	37

#	ARTICLE	IF	CITATIONS
77	Lactobacillus plantarum's survival, functional and potential probiotic properties in the human intestinal tract. <i>International Dairy Journal</i> , 2006, 16, 1018-1028.	1.5	410
78	Probiotics in Gastrointestinal Diseases in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 42, 454-475.	0.9	130
79	Clinical Efficacy of Probiotics. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 43, 550-557.	0.9	93
80	Recommendations for Probiotic Use. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 275-278.	1.1	56
81	Summary of Probiotic Activities of Bifidobacterium lactis HN019. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 776-783.	1.1	41
82	Irritable bowel syndrome: new and emerging therapies. <i>Current Opinion in Internal Medicine</i> , 2006, 5, 297-304.	1.5	7
83	Probiotics and Their Potential Health Claims. <i>Nutrition Reviews</i> , 2006, 64, 265-274.	2.6	160
84	Human Studies on Probiotics: What Is Scientifically Proven. <i>Journal of Food Science</i> , 2004, 69, M137.	1.5	29
85	Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome - a European perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 207-236.	1.9	36
86	Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 183-205.	1.9	141
87	A randomized double-blind placebo-controlled trial of <i>Lactobacillus</i> GG for abdominal pain disorders in children. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 177-184.	1.9	208
89	Inhibitory effects of <i>Lactobacillus reuteri</i> on visceral pain induced by colorectal distension in Sprague-Dawley rats. <i>Gut</i> , 2006, 55, 191-196.	6.1	202
90	Probiotics "Enhancing Health with Beneficial Bacteria. <i>Alternative and Complementary Therapies</i> , 2006, 12, 14-21.	0.1	2
91	Probiotics in Irritable Bowel Syndrome: An Immunomodulatory Strategy?. <i>Journal of the American College of Nutrition</i> , 2007, 26, 684S-690S.	1.1	15
92	Probiotics potentiate IL-6 production in IL-1 ² -treated Caco-2 cells through a heat shock-dependent mechanism. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 293, R1169-R1179.	0.9	31
93	Probiotic Agents in the Treatment of Irritable Bowel Syndrome. <i>Journal of International Medical Research</i> , 2007, 35, 583-589.	0.4	14
94	Probiotics and Prebiotics: Effects on Diarrhea. <i>Journal of Nutrition</i> , 2007, 137, 803S-811S.	1.3	219
95	Synergy between <i>Lactobacillus paracasei</i> and Its Bacterial Products to Counteract Stress-Induced Gut Permeability and Sensitivity Increase in Rats. <i>Journal of Nutrition</i> , 2007, 137, 1901-1907.	1.3	135

#	ARTICLE	IF	CITATIONS
96	Artificial cells for oral delivery of live bacterial cells for therapy. , 2007, , 189-221.		1
97	Prebiotics, Probiotics, and Dietary Fiber in Gastrointestinal Disease. Gastroenterology Clinics of North America, 2007, 36, 47-63.	1.0	63
98	Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut, 2007, 56, 1770-1798.	6.1	677
99	Role of probiotics in correcting abnormalities of colonic flora induced by stress. Gut, 2007, 56, 1495-1497.	6.1	61
101	The role of a probiotics mixture in the treatment of childhood constipation: a pilot study. Nutrition Journal, 2007, 6, 17.	1.5	88
102	Nutritional aspects in patients with functional gastrointestinal disorders and motor dysfunction in the gut. Digestive and Liver Disease, 2007, 39, 495-504.	0.4	9
103	Functional Microbes: Technology for Health Foods. , 0, , 67-84.		0
104	Functional Foods and Gastrointestinal Disorders. , 0, , 153-174.		0
105	Recommendations on Chronic Constipation (Including Constipation Associated with Irritable Bowel) Tj ETQqO 0 0 rgBT /Overlock 10 TF 5	1.8	57
106	Irritable bowel syndrome: symptomatic treatment versus integrative psychotherapy. Contemporary Hypnosis, 2007, 24, 161-177.	0.7	2
107	A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterology and Motility, 2007, 19, 630-637.	1.6	99
108	Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. Journal of Digestive Diseases, 2007, 8, 2-7.	0.7	62
109	Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterology and Motility, 2007, 19, 89-119.	1.6	53
110	Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterology and Motility, 2007, 19, 166-172.	1.6	144
111	Review article: probiotics in gastrointestinal and liver diseases. Alimentary Pharmacology and Therapeutics, 2007, 26, 133-148.	1.9	66
112	Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology and Therapeutics, 2008, 27, 48-57.	1.9	309
113	The role of probiotics in management of irritable bowel syndrome. Current Gastroenterology Reports, 2007, 9, 393-400.	1.1	15
114	Irritable bowel syndrome: Bacteria and inflammationâ€™Clinical relevance now. Current Treatment Options in Gastroenterology, 2007, 10, 312-321.	0.3	22

#	ARTICLE	IF	CITATIONS
116	The patient with refractory diarrhoea. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 485-501.	1.0	2
117	Therapeutic Effect of <i>Lactobacillus acidophilus</i> -SDC 2012, 2013 in Patients with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2714-2718.	1.1	152
118	Influence of <i>E. coli</i> Strain Nissle 1917 (EcN) on Intestinal Gas Dynamics and Abdominal Sensation. <i>Digestive Diseases and Sciences</i> , 2008, 53, 443-450.	1.1	5
119	What is the evidence for the use of probiotics in functional disorders?. <i>Current Gastroenterology Reports</i> , 2008, 10, 379-384.	1.1	14
120	Efficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 1775-1780.	0.7	127
121	Probiotics, Prebiotics, and Synbiotics. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2008, 111, 1-66.	0.6	574
122	Review article: the psychoneuroimmunology of irritable bowel syndrome – an exploration of interactions between psychological, neurological and immunological observations. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 830-840.	1.9	53
123	The <i>D</i> -alanine content of lipoteichoic acid is crucial for <i>Lactobacillus plantarum</i> -mediated protection from visceral pain perception in a rat colorectal distension model. <i>Neurogastroenterology and Motility</i> , 2008, 20, 843-850.	1.6	36
124	Effectiveness of Probiotics in the Treatment of Irritable Bowel Syndrome. <i>Pharmacotherapy</i> , 2008, 28, 496-505.	1.2	24
125	Probiotics and Prebiotics in Dietetics Practice. <i>Journal of the American Dietetic Association</i> , 2008, 108, 510-521.	1.3	213
127	Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles. <i>Gastroenterology</i> , 2008, 135, 1877-1891.	0.6	65
128	The Human Microbiome and Probiotics: Implications for Pediatrics. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2008, 38, 309-327.	0.8	17
129	Food Biotechnology. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2008, , .	0.6	12
130	Probiotic food supplement reduces stress-induced gastrointestinal symptoms in volunteers: a double-blind, placebo-controlled, randomized trial. <i>Nutrition Research</i> , 2008, 28, 1-5.	1.3	129
131	Gastrointestinal Microbiota in Irritable Bowel Syndrome: Their Role in Its Pathogenesis and Treatment. <i>American Journal of Gastroenterology</i> , 2008, 103, 1557-1567.	0.2	160
132	Probiotics in Clinical Practice: An Overview. <i>Journal of International Medical Research</i> , 2008, 36, 1A-53A.	0.4	68
133	The Safety of Probiotics. <i>Clinical Infectious Diseases</i> , 2008, 46, S104-S111.	2.9	272
134	New Treatments for Irritable Bowel Syndrome in Women. <i>Women's Health</i> , 2008, 4, 605-622.	0.7	16

#	ARTICLE	IF	CITATIONS
136	Gastrointestinal Microflora and Interactions with Gut Mucosa. , 2008, , 13-38.		5
137	The benefits of probiotics in irritable bowel syndrome. <i>Gastrointestinal Nursing</i> , 2008, 6, 19-22.	0.0	1
138	Vitamin D Supplements for Type 1 Diabetes. <i>Lippincott S Bone and Joint Newsletter</i> , 2008, 34, 8-9.	0.0	0
139	Probiotics; Past, Present, and Future Perspectives. <i>Current Pediatric Reviews</i> , 2008, 4, 96-102.	0.4	1
140	The Evidence to Support Health Claims for Probiotics. <i>Journal of Nutrition</i> , 2008, 138, 1250S-1254S.	1.3	102
141	The Probiotic <i>Lactobacillus acidophilus</i> Stimulates Chloride/Hydroxyl Exchange Activity in Human Intestinal Epithelial Cells. <i>Journal of Nutrition</i> , 2008, 138, 1355-1359.	1.3	80
142	Measuring the Glycemic Index and Glycemic Load. <i>Lippincott S Bone and Joint Newsletter</i> , 2008, 34, 3-4.	0.0	0
143	When Are Probiotics Effective?. <i>Lippincott S Bone and Joint Newsletter</i> , 2008, 34, 7-8.	0.0	0
144	Probiotics and Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, S214-S217.	1.1	25
145	Controversies in Using the Glycemic Index. <i>Lippincott S Bone and Joint Newsletter</i> , 2008, 34, 1-4.	0.0	0
146	Probiotic Deaths Spur Renewed Scrutiny On Safety. <i>Lippincott S Bone and Joint Newsletter</i> , 2008, 34, 4-6.	0.0	0
147	Are Dannon's Probiotic Claims "Bogus"? <i>Lippincott S Bone and Joint Newsletter</i> , 2008, 34, 6.	0.0	0
149	news bites. <i>Lippincott S Bone and Joint Newsletter</i> , 2008, 34, 12.	0.0	0
150	The Efficacy of Probiotics in IBS. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, S85-S90.	1.1	16
151	Recommendations for Probiotic Use"2008. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, S104-S108.	1.1	120
152	Meta-analysis of probiotics for the treatment of irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2008, 14, 2650.	1.4	299
153	Generic and Product-Specific Health Claim Processes for Functional Foods across Global Jurisdictions3. <i>Journal of Nutrition</i> , 2008, 138, 1228S-1236S.	1.3	33
154	Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells. <i>Biologics: Targets and Therapy</i> , 2008, 2, 355.	3.0	8

#	ARTICLE	IF	CITATIONS
155	Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. <i>World Journal of Gastroenterology</i> , 2009, 15, 2887.	1.4	245
156	Medical Journal Watch: Context and Applications. <i>Alternative and Complementary Therapies</i> , 2009, 15, 90-95.	0.1	0
157	Review: Do probiotics improve symptoms in patients with irritable bowel syndrome?. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, S37-S44.	1.4	23
158	Herbs and Biological Agents. , 2009, , 106-130.		0
159	Novel strategies and future landmarks in the treatment of irritable bowel syndrome. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 603-613.	0.2	1
160	Randomized Controlled Treatment Trial of Irritable Bowel Syndrome with a Probiotic E.-coli Preparation (DSM17252) Compared to Placebo. <i>Zeitschrift Fur Gastroenterologie</i> , 2009, 47, 209-214.	0.2	98
161	Developing effective probiotic products: bioavailability and other factors. , 2009, , 230-262.		0
162	Effect of <i>Lactobacillus plantarum</i> 299v treatment in an animal model of irritable bowel syndrome. <i>Microbial Ecology in Health and Disease</i> , 2009, 21, 33-37.	3.8	6
163	Influence of fruit drinks with or without <i>Lactobacillus Lp299v</i> on the gastrointestinal uptake of paracetamol in man. <i>BMC Research Notes</i> , 2009, 2, 45.	0.6	3
165	Heterologous Expression of Oxalate Decarboxylase in <i>Lactobacillus plantarum</i> NC8. <i>Current Microbiology</i> , 2009, 58, 117-121.	1.0	31
166	A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. <i>BMC Gastroenterology</i> , 2009, 9, 15.	0.8	233
167	Proteomic analysis of cell surface-associated proteins from probiotic <i>Lactobacillus plantarum</i> . <i>FEMS Microbiology Letters</i> , 2009, 297, 61-66.	0.7	55
168	Irritable bowel syndrome: Role of food in pathogenesis and management. <i>Journal of Digestive Diseases</i> , 2009, 10, 237-246.	0.7	76
169	<i>Lactococcus lactis</i> subsp. <i>cremoris</i> FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. <i>International Immunopharmacology</i> , 2009, 9, 1444-1451.	1.7	89
170	Clinical evaluation of <i>Lactobacillus paracasei</i> subsp. <i>paracasei</i> F19 with gluco-oligosaccharides in the short-term treatment of irritable bowel syndrome. <i>Microbial Ecology in Health and Disease</i> , 2009, 21, 28-32.	3.8	5
171	The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2009, 104, 1033-1049.	0.2	323
172	An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2009, 104, S1-S35.	0.2	511
173	Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. <i>Nutrition Journal</i> , 2009, 8, 4.	1.5	54

#	ARTICLE	IF	CITATIONS
174	Microflora imbalance and gastrointestinal diseases. Digestive and Liver Disease Supplements, 2009, 3, 35-39.	0.2	14
177	Fast-Track Surgery May Reduce Complications Following Major Colonic Surgery. Diseases of the Colon and Rectum, 2009, 52, 1804.	0.7	0
179	Efficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials. Diseases of the Colon and Rectum, 2009, 52, 1805.	0.7	8
181	22 Beeinflussung des Reizdarmsyndroms und der Obstipation durch Pro- und Präbiotika. , 2009, , .		0
182	Effects of dietary amines on the gut and its vasculature. British Journal of Nutrition, 2009, 101, 1645-1652.	1.2	36
183	The Impact of Probiotic on Gut Health. Current Drug Metabolism, 2009, 10, 68-78.	0.7	190
184	Surgical Treatment of Anal Condylomata Acuminata. Diseases of the Colon and Rectum, 2009, 52, 1803.	0.7	2
185	Microbiology of the Human Intestinal Tract and Approaches for Its Dietary Modulation. Current Pharmaceutical Design, 2009, 15, 1403-1414.	0.9	77
186	Intake of Lactobacillus plantarum Reduces Certain Gastrointestinal Symptoms During Treatment With Antibiotics. Journal of Clinical Gastroenterology, 2010, 44, 106-112.	1.1	95
189	A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterology, 2010, 10, 16.	0.8	80
190	Microarray Analysis of Probiotics Effectiveness. , 2010, , 479-495.		0
191	The Serum Metabolite Response to Diet Intervention with Probiotic Acidified Milk in Irritable Bowel Syndrome Patients Is Indistinguishable from that of Non-Probiotic Acidified Milk by 1H NMR-Based Metabonomic Analysis. Nutrients, 2010, 2, 1141-1155.	1.7	16
192	Anti-inflammatory Activities of <i>Lactococcus lactis</i> subsp. <i>cremoris</i> FC in <i>In Vitro</i> and <i>In Vivo</i> Gut Inflammation Models. Bioscience and Microflora, 2010, 29, 169-178.	0.5	5
193	The Role of Probiotics in the Treatment of Irritable Bowel Syndrome. , 2010, , 513-528.		3
194	Treating irritable bowel syndrome with probiotics: the evidence. Proceedings of the Nutrition Society, 2010, 69, 187-194.	0.4	51
195	Medical Journal Watch. Alternative and Complementary Therapies, 2010, 16, 59-63.	0.1	0
196	Guidance for Substantiating the Evidence for Beneficial Effects of Probiotics: Probiotics in Chronic Inflammatory Bowel Disease and the Functional Disorder Irritable Bowel Syndrome. Journal of Nutrition, 2010, 140, 690S-697S.	1.3	79
198	The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut, 2010, 59, 325-332.	6.1	588

#	ARTICLE	IF	CITATIONS
199	Pathogenic Factors Involved in the Development of Irritable Bowel Syndrome: Focus on a Microbial Role. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 961-975.	1.9	28
200	Probiotics and Host Defense, Health Claim and Evidences. , 2010, , 385-422.		0
202	Dietary Components and Immune Function. , 2010, , .		13
203	Probiotics and Prebiotics. , 2010, , 205-227.		14
204	Probiotic Bacteria and Enteric Infections. , 2011, , .		4
205	Probiotics for the Control of Parasites: An Overview. <i>Journal of Parasitology Research</i> , 2011, 2011, 1-11.	0.5	97
206	Effect of Lactobacilli on Paracellular Permeability in the Gut. <i>Nutrients</i> , 2011, 3, 104-117.	1.7	132
207	Irritable Bowel Syndrome, Gut Microbiota and Probiotics. <i>Journal of Neurogastroenterology and Motility</i> , 2011, 17, 252-266.	0.8	168
208	Do probiotic preparations for humans really have efficacy?. <i>Microbial Ecology in Health and Disease</i> , 2011, 22, 10128.	3.8	15
209	Recommendations for Probiotic Useâ€”2011 Update. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, S168-S171.	1.1	180
210	Current and Future Applications of Probiotics. <i>Current Nutrition and Food Science</i> , 2011, 7, 170-180.	0.3	3
211	The Rationale and Clinical Effectiveness of Probiotics in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, S145-S148.	1.1	40
212	Scientific Opinion on the substantiation of health claims related to <i>Lactobacillus plantarum</i> 299v and reduction of flatulence and bloating (ID 902), and protection of DNA, proteins and lipids from oxidative damage (ID 1083) pursuant to Article 13(1) of Re. <i>EFSA Journal</i> , 2011, 9, 2037.	0.9	2
213	Treatment of irritable bowel syndrome. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 275-282.	0.7	30
214	Do probiotics offer opportunities to manipulate the periodontal oral microbiota?. <i>Journal of Clinical Periodontology</i> , 2011, 38, 159-177.	2.3	131
215	Indications for the Use of Probiotics in Gastrointestinal Diseases. <i>Digestive Diseases</i> , 2011, 29, 574-587.	0.8	60
216	A GCâ€”MS-based metabonomic investigation of blood serum from irritable bowel syndrome patients undergoing intervention with acidified milk products. <i>European Food Research and Technology</i> , 2011, 233, 1013-1021.	1.6	18
217	Is <i>Bifidobacterium breve</i> effective in the treatment of childhood constipation? Results from a pilot study. <i>Nutrition Journal</i> , 2011, 10, 19.	1.5	52

#	ARTICLE	IF	CITATIONS
220	Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of <i>Pseudomonas aeruginosa</i> in irritable bowel syndrome. <i>Journal of Medical Microbiology</i> , 2011, 60, 236-245.	0.7	115
221	Medical Journal Watch: Context and Applications. <i>Alternative and Complementary Therapies</i> , 2011, 17, 57-61.	0.1	0
222	Probiotics and Irritable Bowel Syndrome. <i>Microbial Ecology in Health and Disease</i> , 2012, 23, .	3.8	7
223	Prebiotics, probiotics and digestive health. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2012, 15, 580-585.	1.3	40
224	Probiotics use to treat irritable bowel syndrome. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1323-1334.	1.4	27
225	Mucosal Permeability and Immune Activation as Potential Therapeutic Targets of Probiotics in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, S52-S55.	1.1	67
226	Probiotics in the critically ill. <i>Critical Care Medicine</i> , 2012, 40, 3290-3302.	0.4	126
227	The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 220-227.	1.1	199
228	A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics. <i>Inflammopharmacology</i> , 2012, 20, 251-266.	1.9	25
229	Probiotics in the Management of Functional Bowel Disorders. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 805-819.	1.0	20
230	The Shortcomings of Clinical Trials Assessing the Efficacy of Probiotics in Irritable Bowel Syndrome. <i>Journal of Alternative and Complementary Medicine</i> , 2012, 18, 112-119.	2.1	14
231	Bacterial Flora as a Cause or Treatment of Chronic Diarrhea. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 581-602.	1.0	17
232	A Meta-Analysis of Probiotic Efficacy for Gastrointestinal Diseases. <i>PLoS ONE</i> , 2012, 7, e34938.	1.1	375
233	Clinical trial: <i>Lactobacillus plantarum</i> (DSM 9843) improves symptoms of irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2012, 18, 4012.	1.4	226
234	Probiotics: defenders of gastrointestinal habitats. <i>Gastroenterology Insights</i> , 2012, 4, 22.	0.7	2
235	EFFECTOS CLÍNICOS DE LOS PROBIÓTICOS: QUÉ DICE LA EVIDENCIA. <i>Revista Chilena De Nutricion</i> , 2012, 39, 98-110.	0.1	8
237	Cholesterol-Lowering Probiotics as Potential Biotherapeutics for Metabolic Diseases. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-14.	3.8	516
238	Review article: probiotics for the treatment of irritable bowel syndrome – focus on lactic acid bacteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 403-413.	1.9	175

#	ARTICLE	IF	CITATIONS
239	Randomised clinical trial: efficacy of <i>Lactobacillus paracasei</i> -enriched artichokes in the treatment of patients with functional constipation – a double-blind, controlled, crossover study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 441-450.	1.9	74
240	<i>Integrative Medicine in Allergy and Immunology. Clinical Reviews in Allergy and Immunology</i> , 2013, 44, 208-228.	2.9	16
241	Probiotics: a new frontier for infection control. <i>Journal of Hospital Infection</i> , 2013, 84, 1-4.	1.4	20
242	Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 995-1009.	0.6	60
243	The Pharmacobiotic Potential of the Gastrointestinal Tract Microbiome – Probiotic Connect: A Brief Commentary. <i>Drug Development Research</i> , 2013, 74, 353-359.	1.4	5
244	<i>Intestinal Microflora and Diet in Health.</i> , 2013, , 719-738.		4
245	An overview of the last advances in probiotic and prebiotic field. <i>LWT - Food Science and Technology</i> , 2013, 50, 1-16.	2.5	361
247	Anchorless surface associated glycolytic enzymes from <i>Lactobacillus plantarum</i> 299v bind to epithelial cells and extracellular matrix proteins. <i>Microbiological Research</i> , 2013, 168, 245-253.	2.5	59
248	Acknowledgements. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 289-289.	1.4	11
249	Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G529-G541.	1.6	93
250	Probiotics and clinical effects: is the number what counts?. <i>Journal of Chemotherapy</i> , 2013, 25, 193-212.	0.7	58
251	Diet, Microbiome, and the Intestinal Epithelium: An Essential Triumvirate?. <i>BioMed Research International</i> , 2013, 2013, 1-12.	0.9	43
252	Profermin is Efficacious in Patients with Active Ulcerative Colitis – A Randomized Controlled Trial. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2584-2592.	0.9	16
253	Use of <i>Lactobacillus</i> in Prevention of Recurrences of <i>Clostridium difficile</i> Infection in Solid Organ Transplant Recipients. <i>Infectious Diseases in Clinical Practice</i> , 2013, 21, 292-298.	0.1	5
254	Development of Microencapsulation Delivery System for Long-Term Preservation of Probiotics as Biotherapeutics Agent. <i>BioMed Research International</i> , 2013, 2013, 1-21.	0.9	114
255	Fecal excretion of <i>Bifidobacterium infantis</i> 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. <i>Gut Microbes</i> , 2013, 4, 201-211.	4.3	99
256	Potential of probiotics as pharmaceutical agent: a review. <i>British Food Journal</i> , 2013, 115, 1658-1687.	1.6	8
257	Intestinal microbiota in functional bowel disorders: a Rome foundation report. <i>Gut</i> , 2013, 62, 159-176.	6.1	776

#	ARTICLE	IF	CITATIONS
258	The benefits of probiotics in irritable bowel syndrome. <i>Gastrointestinal Nursing</i> , 2013, 11, 21-24.	0.0	0
259	Actual concept of "probiotics": Is it more functional to science or business?. <i>World Journal of Gastroenterology</i> , 2013, 19, 1527.	1.4	51
260	Unraveling the ties between irritable bowel syndrome and intestinal microbiota. <i>World Journal of Gastroenterology</i> , 2014, 20, 2470.	1.4	67
261	Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3. <i>Asian Journal of Andrology</i> , 2014, 16, 735.	0.8	15
262	The microbiota-gut-brain axis in functional gastrointestinal disorders. <i>Gut Microbes</i> , 2014, 5, 419-429.	4.3	112
263	Irritable bowel syndrome: the problem and the problem of treating it – is there a role for probiotics?. <i>Proceedings of the Nutrition Society</i> , 2014, 73, 470-476.	0.4	7
264	Therapeutic Effects of Biobran, Modified Arabinoxylan Rice Bran, in Improving Symptoms of Diarrhea Predominant or Mixed Type Irritable Bowel Syndrome: A Pilot, Randomized Controlled Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-6.	0.5	26
265	Recommendations for Probiotic Use in Humans – A 2014 Update. <i>Pharmaceuticals</i> , 2014, 7, 999-1007.	1.7	52
267	Nonsteroidal Anti-inflammatory Drugs, Proton Pump Inhibitors, and Gastrointestinal Injury: Contrasting Interactions in the Stomach and Small Intestine. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1699-1709.	1.4	70
268	Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome. <i>Current Medical Research and Opinion</i> , 2014, 30, 1405-1415.	0.9	18
269	Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive <sc>IBS</sc> patients. <i>Neurogastroenterology and Motility</i> , 2014, 26, 705-714.	1.6	54
270	Probiotics, prebiotics and the gastrointestinal tract in health and disease. <i>Inflammopharmacology</i> , 2014, 22, 135-154.	1.9	49
271	<i>Laminaria japonica</i> Combined with Probiotics Improves Intestinal Microbiota: A Randomized Clinical Trial. <i>Journal of Medicinal Food</i> , 2014, 17, 76-82.	0.8	14
272	Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1547-1561.	0.2	595
273	American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2014, 109, S2-S26.	0.2	503
274	Randomized clinical trial: Effect of <i>Lactobacillus plantarum</i> 299 v on symptoms of irritable bowel syndrome. <i>Nutrition</i> , 2014, 30, 1151-1157.	1.1	73
275	Probiotic strain <i>Lactobacillus plantarum</i> 299v increases iron absorption from an iron-supplemented fruit drink: a double-isotope cross-over single-blind study in women of reproductive age. <i>British Journal of Nutrition</i> , 2015, 114, 1195-1202.	1.2	76
276	Comparative genome-based identification of a cell wall-anchored protein from <i>Lactobacillus plantarum</i> increases adhesion of <i>Lactococcus lactis</i> to human epithelial cells. <i>Scientific Reports</i> , 2015, 5, 14109.	1.6	29

#	ARTICLE	IF	CITATIONS
277	Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000052.	1.1	34
278	Genome architecture of <i>Lactobacillus plantarum</i> PS128, a probiotic strain with potential immunomodulatory activity. <i>Gut Pathogens</i> , 2015, 7, 22.	1.6	29
279	Recommendations for Probiotic Use—2015 Update. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, S69-S73.	1.1	104
280	The Interplay of the Gut Microbiome, Bile Acids, and Volatile Organic Compounds. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-6.	0.7	72
281	The Effect of <i>Lactobacillus plantarum</i> 299v on the Incidence of <i>Clostridium difficile</i> Infection in High Risk Patients Treated with Antibiotics. <i>Nutrients</i> , 2015, 7, 10179-10188.	1.7	38
282	Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 471-485.	0.8	56
283	Visceral Pain and Gastrointestinal Microbiome. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 172-181.	0.8	49
284	Colon Cancer Prevention through Probiotics: An Overview. <i>Journal of Cancer Science & Therapy</i> , 2015, 07, .	1.7	15
285	New Approaches for Bacteriotherapy: Prebiotics, New-Generation Probiotics, and Synbiotics. <i>Clinical Infectious Diseases</i> , 2015, 60, S108-S121.	2.9	194
286	Gender in Probiotic Use. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 93-94.	1.1	1
287	Effects of Probiotic Intake and Gender on Nontyphoid Salmonella Infection. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 116-123.	1.1	17
288	Early life microbial colonization of the gut and intestinal development differ between genetically divergent broiler lines. <i>BMC Genomics</i> , 2015, 16, 418.	1.2	107
289	Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. <i>World Journal of Gastroenterology</i> , 2016, 22, 2219-2241.	1.4	249
290	Role of <i>Lactobacillus plantarum</i> MTCC1325 in membrane-bound transport ATPases system in Alzheimer's disease-induced rat brain. <i>BiolImpacts</i> , 2016, 6, 203-209.	0.7	26
291	Oral Administration of <i>Lactobacillus plantarum</i> 299v Reduces Cortisol Levels in Human Saliva during Examination Induced Stress: A Randomized, Double-Blind Controlled Trial. <i>International Journal of Microbiology</i> , 2016, 2016, 1-7.	0.9	46
292	British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). <i>Journal of Human Nutrition and Dietetics</i> , 2016, 29, 549-575.	1.3	237
293	British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5	1.3	237
294	Probiotic Bacterial and Fungal Strains: Claims with Evidence. <i>Digestive Diseases</i> , 2016, 34, 251-259.	0.8	31

#	ARTICLE	IF	CITATIONS
295	Encapsulation of Lactobacillus plantarum in porous maize starch. LWT - Food Science and Technology, 2016, 74, 542-549.	2.5	67
296	What's bugging your teen? The microbiota and adolescent mental health. Neuroscience and Biobehavioral Reviews, 2016, 70, 300-312.	2.9	44
297	Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation. Current Hematologic Malignancy Reports, 2016, 11, 19-28.	1.2	52
298	Exercise and gut immune function: evidence of alterations in colon immune cell homeostasis and microbiome characteristics with exercise training. Immunology and Cell Biology, 2016, 94, 158-163.	1.0	97
299	The Cholesterol-Lowering Effects of Probiotic Bacteria on Lipid Metabolism. , 2016, , 699-722.		3
300	Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease. Drug Safety, 2016, 39, 295-305.	1.4	11
301	Metabolic role of lactobacilli in weight modification in humans and animals. Microbial Pathogenesis, 2017, 106, 182-194.	1.3	85
302	Consenso mexicano sobre probióticos en gastroenterología. Revista De Gastroenterología De México, 2017, 82, 156-178.	0.4	20
303	Lactobacillus plantarum and Its Probiotic and Food Potentialities. Probiotics and Antimicrobial Proteins, 2017, 9, 111-122.	1.9	244
304	The Mexican consensus on probiotics in gastroenterology. Revista De Gastroenterología De México (English Edition), 2017, 82, 156-178.	0.1	12
305	Probiotic strains and mechanistic insights for the treatment of type 2 diabetes. Endocrine, 2017, 58, 207-227.	1.1	33
306	Close association between intestinal microbiota and irritable bowel syndrome. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 2303-2317.	1.3	16
307	Probiotics in Newborns and Children. Pediatric Clinics of North America, 2017, 64, 1271-1289.	0.9	16
309	Probiotic potential of Lactobacilli with antagonistic activity against pathogenic strains: An in vitro validation for the production of inhibitory substances. Biomedical Journal, 2017, 40, 270-283.	1.4	110
310	The microbiome and disorders of the central nervous system. Pharmacology Biochemistry and Behavior, 2017, 160, 1-13.	1.3	47
311	Oral probiotic treatment of Lactobacillus rhamnosus Lcr35 [®] prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress. Journal of Applied Microbiology, 2017, 122, 188-200.	1.4	24
312	A genetic diversity study of antifungal Lactobacillus plantarum isolates. Food Control, 2017, 72, 83-89.	2.8	13
313	Intestinal Microbiota and Diet in Health. , 2017, , 811-834.		2

#	ARTICLE	IF	CITATIONS
314	Beneficial Influences of <i>Lactobacillus plantarum</i> on Human Health and Disease. , 2017, , 109-117.		7
315	Relationship of peripheral blood neutrophil to lymphocyteratio and irritable bowel syndrome. Turkish Journal of Medical Sciences, 2017, 47, 1067-1071.	0.4	9
316	A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). Probiotics and Antimicrobial Proteins, 2018, 10, 466-477.	1.9	27
317	Freeze-dried alginate-silica microparticles as carriers of probiotic bacteria in apple juice and beer. LWT - Food Science and Technology, 2018, 91, 175-179.	2.5	27
318	Dysbiosis in Functional Bowel Disorders. Annals of Nutrition and Metabolism, 2018, 72, 296-306.	1.0	46
319	Bacteriocin biosynthesis contributes to the anti-inflammatory capacities of probiotic <i>Lactobacillus plantarum</i> . Beneficial Microbes, 2018, 9, 333-344.	1.0	35
320	Vibrational spectroscopy combined with transcriptomic analysis for investigation of bacterial responses towards acid stress. Applied Microbiology and Biotechnology, 2018, 102, 333-343.	1.7	14
321	Guidelines on the management of irritable bowel syndrome. Przegląd Gastroenterologiczny, 2018, 13, 259-288.	0.3	24
322	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2018, 48, 1044-1060.	1.9	423
323	Adhesion Properties of Food-Associated <i>Lactobacillus plantarum</i> Strains on Human Intestinal Epithelial Cells and Modulation of IL-8 Release. Frontiers in Microbiology, 2018, 9, 2392.	1.5	53
324	Probiotics in human health and disease: from nutraceuticals to pharmabiotics. Journal of Microbiology, 2018, 56, 773-782.	1.3	90
325	Functional Starch and Applications in Food. , 2018, , .		7
326	Lacto-fermented sauerkraut improves symptoms in IBS patients independent of product pasteurisation – a pilot study. Food and Function, 2018, 9, 5323-5335.	2.1	56
327	Porous Starch and Its Applications. , 2018, , 91-117.		5
328	The prevalence and characteristics of complementary medicine use by Australian and American adults living with gastrointestinal disorders: A systematic review. Complementary Therapies in Medicine, 2018, 41, 52-60.	1.3	13
329	Sucrose metabolism alters <i>Lactobacillus plantarum</i> survival and interactions with the microbiota in the digestive tract. FEMS Microbiology Ecology, 2018, 94, .	1.3	16
330	American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2018, 113, 1-18.	0.2	262
331	Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. Journal of Neurogastroenterology and Motility, 2018, 24, 197-215.	0.8	33

#	ARTICLE	IF	CITATIONS
332	The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome. <i>Foods</i> , 2018, 7, 13.	1.9	59
333	A New Generation of Probiotic Functional Beverages Using Bioactive Compounds From Agro-Industrial Waste. , 2019, , 483-528.		15
334	Microbiome and Allogeneic Hematopoietic Stem Cell Transplantation. , 2019, , 141-154.		0
335	CRISPR Interference for Rapid Knockdown of Essential Cell Cycle Genes in <i>Lactobacillus plantarum</i> . <i>MSphere</i> , 2019, 4, .	1.3	36
336	Gallotannins and <i>Lactobacillus plantarum</i> WCFS1 Mitigate High-Fat Diet-Induced Inflammation and Induce Biomarkers for Thermogenesis in Adipose Tissue in Gnotobiotic Mice. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1800937.	1.5	20
337	Regional characteristics of <i>Lactobacillus plantarum</i> group strains isolated from two kinds of Japanese post-fermented teas, Ishizuchi-kurocha and Awa-bancha. <i>Bioscience of Microbiota, Food and Health</i> , 2019, 38, 11-22.	0.8	17
338	Therapeutic Potential of Probiotics and Prebiotics. , 0, , .		5
339	The effects of a multispecies probiotic supplement on inflammatory markers and episodic and chronic migraine characteristics: A randomized double-blind controlled trial. <i>Cephalalgia</i> , 2019, 39, 841-853.	1.8	60
340	Gastrointestinal disorders-induced pain. <i>Gene Reports</i> , 2020, 18, 100580.	0.4	1
341	Probiotics and prebiotics, including fibers and medicinal foods. , 2020, , 587-600.		3
342	Irritable bowel syndrome and the gut microbiota. <i>Journal of the Royal Society of New Zealand</i> , 2020, 50, 470-490.	1.0	2
343	Targeting the gut microbiota for the treatment of irritable bowel syndrome. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 160-170.	0.8	29
344	Nutritional Therapies for Irritable Bowel Syndrome: a Focus on Prebiotics and Probiotics. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 729-739.	0.3	0
345	The use of <i>Lactobacillus plantarum</i> 299v (DSM 9843) in cancer patients receiving home enteral nutrition â€” study protocol for a randomized, double-blind, and placebo-controlled trial. <i>Nutrition Journal</i> , 2020, 19, 98.	1.5	20
346	Effect of probiotic supplementation on migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials. <i>Nutritional Neuroscience</i> , 2022, 25, 511-518.	1.5	9
347	The Effect of <i>Lactobacillus plantarum</i> 299v on Iron Status and Physical Performance in Female Iron-Deficient Athletes: A Randomized Controlled Trial. <i>Nutrients</i> , 2020, 12, 1279.	1.7	32
348	<i>Saccharomyces boulardii</i> CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. <i>Current Microbiology</i> , 2020, 77, 1987-1996.	1.0	39
349	Feeding lactobacilli impacts lupus progression in (NZBxNZW)F1 lupus-prone mice by enhancing immunoregulation. <i>Autoimmunity</i> , 2020, 53, 323-332.	1.2	19

#	ARTICLE	IF	CITATIONS
350	AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders. <i>Gastroenterology</i> , 2020, 159, 708-738.e4.	0.6	71
351	<i>Fusobacterium nucleatum</i> Causes Microbial Dysbiosis and Exacerbates Visceral Hypersensitivity in a Colonization-Independent Manner. <i>Frontiers in Microbiology</i> , 2020, 11, 1281.	1.5	26
352	The efficacy and safety of probiotics in patients with irritable bowel syndrome: Evidence based on 35 randomized controlled trials. <i>International Journal of Surgery</i> , 2020, 75, 116-127.	1.1	46
353	Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 332.	1.6	56
354	Effects of probiotics on bowel function restoration following ileostomy closure in rectal cancer patients: a randomized controlled trial. <i>Colorectal Disease</i> , 2021, 23, 901-910.	0.7	23
355	Advances in Probiotics for Sustainable Food and Medicine. <i>Microorganisms for Sustainability</i> , 2021, , .	0.4	3
356	Probiotic Research in Therapeutics. , 2021, , .		1
357	Gut Microbiome and Gastrointestinal Disorders. <i>The Microbiomes of Humans, Animals, Plants, and the Environment</i> , 2021, , 41-91.	0.2	0
358	Isolation, identification, and impact on intestinal barrier integrity of <i>Lactiplantibacillus plantarum</i> from fresh tea leaves (<i>Camellia sinensis</i>). <i>Bioscience of Microbiota, Food and Health</i> , 2021, 40, 186-195.	0.8	2
359	Strain-Specific and Outcome-Specific Efficacy of Probiotics for the Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
361	The role of gut microbiota in the treatment of irritable bowel syndrome. <i>Reviews in Medical Microbiology</i> , 2022, 33, e89-e104.	0.4	6
362	Oral intake of <i>Lactobacillus plantarum</i> 14 extract alleviates TLR2- and AMPK-mediated obesity-associated disorders in high-fat diet-induced obese C57BL/6J mice. <i>Cell Proliferation</i> , 2021, 54, e13039.	2.4	34
363	Identification of Bile Salt Hydrolase and Bile Salt Resistance in a Probiotic Bacterium <i>Lactobacillus gasser</i> JCM1131T. <i>Microorganisms</i> , 2021, 9, 1011.	1.6	15
364	<i>Lactiplantibacillus plantarum</i> 299v (LP299V [®]): three decades of research. <i>Beneficial Microbes</i> , 2021, 12, 441-465.	1.0	36
365	Medical Therapies for Diarrhea-Predominant Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 611-637.	1.0	1
366	<i>Clostridioides difficile</i> Infection in Patients with Chronic Kidney Disease: A Systematic Review. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	1
367	Why Use Nutraceutical Strategies for the Irritable Bowel Syndrome?. <i>Current Medicinal Chemistry</i> , 2022, 29, 2075-2092.	1.2	2
368	Inclusion of Probiotics in Beverages. , 2004, , 247-257.		1

#	ARTICLE	IF	CITATIONS
369	Gastrointestinal Tract Commensal Bacteria and Probiotics: Influence on End-Organ Physiology. Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques, 2015, 70, 1-33.	0.6	4
370	Probiotics in Clinical Practice as Therapeutics Against Enteric Disorders. , 2011, , 355-373.		1
371	Probiotics, with special emphasis on their role in the management of irritable bowel syndrome. South African Journal of Clinical Nutrition, 2011, 24, 63-71.	0.3	2
372	Prebiotics in Human Medicine. , 0, , 299-306.		1
374	Synergistic Protection of Combined Probiotic Conditioned Media against Neonatal Necrotizing Enterocolitis-Like Intestinal Injury. PLoS ONE, 2013, 8, e65108.	1.1	47
375	Are There Any Different Effects of Bifidobacterium, Lactobacillus and Streptococcus on Intestinal Sensation, Barrier Function and Intestinal Immunity in PI-IBS Mouse Model?. PLoS ONE, 2014, 9, e90153.	1.1	75
376	An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults. PLoS ONE, 2017, 12, e0187964.	1.1	99
377	An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2009, 104, S8-S35.	0.2	140
378	Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial. Cellular and Molecular Biology, 2017, 63, 122.	0.3	8
379	<i>Lactobacillus plantarum</i> B7 attenuates <i>Salmonella typhimurium</i> infection in mice: preclinical study in vitro and in vivo. Asian Biomedicine, 2019, 12, 211-218.	0.2	3
380	Probiotics and Health. Journal of Biology and Today's World, 2013, 2, .	0.1	1
382	The effects of three novel probiotics isolated from the Korean fermented food Kimchi on the stress-induced defecation of rats. Precision and Future Medicine, 2020, 4, 31-36.	0.5	1
384	Updates on treatment of irritable bowel syndrome. World Journal of Gastroenterology, 2008, 14, 2639.	1.4	51
385	Safety and efficacy of Profermin [®] to induce remission in ulcerative colitis. World Journal of Gastroenterology, 2012, 18, 1773.	1.4	15
386	Effect of areca on contraction of colonic muscle strips in rats. World Journal of Gastroenterology, 2002, 8, 350.	1.4	11
387	Treatment of irritable bowel syndrome with probiotics: An etiopathogenic approach at last?. Revista Espanola De Enfermedades Digestivas, 2009, 101, 553-64.	0.1	46
388	Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Revista Espanola De Enfermedades Digestivas, 2013, 105, 19-36.	0.1	84
389	Using Calculus to Model the Growth of <i>L. Plantarum</i> Bacteria. Undergraduate Journal of Mathematical Modeling: One + Two, 2013, 1, .	0.0	2

#	ARTICLE	IF	CITATIONS
390	A Review on Some Chemical Engineering and Microbiological Aspects Considered in the Production of Highly Concentrated Probiotic Cultures and Bacteriocins by Lactococci and Lactobacilli. ISRN Chemical Engineering, 2012, 2012, 1-24.	1.2	2
391	Improvement of Health by Probiotics: The Roles on Human Gut and Immune Modulation. British Microbiology Research Journal, 2016, 15, 1-14.	0.2	1
392	The antiinflammatory and antifibrotic effect of olive phenols and Lactiplantibacillus plantarum IMC513 in dextran sodium sulfateâ€“induced chronic colitis. Nutrition, 2022, 94, 111511.	1.1	8
393	Lactiplantibacillus plantarumâ€“Nomad and Ideal Probiotic. Frontiers in Microbiology, 2021, 12, 712236.	1.5	58
394	Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. EclinicalMedicine, 2021, 41, 101154.	3.2	32
395	Developing and approving health claims for functional dairy products. , 2003, , 246-260.		0
396	Fiber (Prebiotics) and Probiotics. , 2005, , 151-171.		0
397	Functional dairy products for gastrointestinal infections and dysfunction. , 2007, , 63-89.		1
398	Role of Microflora in Disease. , 2009, , 29-39.		0
401	Improvement of functional bloating by an enterovaccine: a preliminary study. Revista Espanola De Enfermedades Digestivas, 2009, 101, 619-22.	0.1	1
402	Application of Functional Dairy Products from IBS to IBD. , 2009, , 375-393.		0
403	Probiotics and Inflammatory Immune Responses. , 2010, , 591-610.		0
404	Medical Treatment of Irritable Bowel Syndrome, Constipation, and Obstructed Defecation. , 2010, , 539-543.		0
405	Neuroimmunomodulation, Stressâ€“Nutrition Interactions and Diet. , 2010, , 75-87.		0
406	The Intestinal Microbiota and Intestinal Disease: Irritable Bowel Syndrome. , 2012, , 211-222.		0
410	Current Strategies in the Management of Irritable Bowel Syndrome. Internal Medicine: Open Access, 2014, s1, .	0.0	1
411	Molecular Verification of Two Potent Bacteria Isolated from Darfiyeh Cheese: <i>Lactococcus lactis</i> Subsp. <i>Lactis</i> and <i>Lactobacillus plantarum</i>. Advances in Microbiology, 2014, 04, 609-615.	0.3	0
412	Probiotic Effect of Lebanese Darfiyeh Cheese: A Randomized Case Control Prospective Study in the Elderly. Food and Nutrition Sciences (Print), 2015, 06, 1086-1094.	0.2	1

#	ARTICLE	IF	CITATIONS
449	Mechanisms and applications of probiotics in healthcare industry. , 2022, , 225-257.		5
450	Probiotics in the Management of Mental and Gastrointestinal Post-COVID Symptomes. Journal of Clinical Medicine, 2022, 11, 5155.	1.0	5
451	Genomic analysis and in vivo efficacy of <i>Pediococcus acidilactici</i> as a potential probiotic to prevent hyperglycemia, hypercholesterolemia and gastrointestinal infections. Scientific Reports, 2022, 12, .	1.6	8
452	A postbiotic fermented oat gruel may have a beneficial effect on the colonic mucosal barrier in patients with irritable bowel syndrome. Frontiers in Nutrition, 0, 9, .	1.6	4
453	Leaky Gut and the Ingredients That Help Treat It: A Review. Molecules, 2023, 28, 619.	1.7	28
454	Gut microbiota diversity in human strongyloidiasis differs little in two different regions in endemic areas of Thailand. PLoS ONE, 2022, 17, e0279766.	1.1	1